Guidelines for the use of cyclosporin A in psoriasis. State of the art;Linee guida al trattamento della psoriasi con ciclosporina A

Giornale Italiano di Dermatologia e Venereologia

Volumn 136, Issue 6, 2001, Pages 463-470

  Cassano, N ^a   Colombo, D ^a   Vena, G A ^a  

^a NONE

Author keywords

Cyclosporin A; Psoriasis; Safety; Therapy; Tolerability

Indexed keywords

CYCLOSPORIN A;

DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC ASPECT; HUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSORIASIS; REVIEW; SIDE EFFECT;

EID: 0035572517     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. The mechanism of action of cyclosporin A in the treatment of psoriasis
2. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis
3. Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy
4. Effects of cyclosporin A on immune activation markers in patients with active psoriasis
5. Cyclosporin A for psoriasis
6. Overexpression of monocyte-derived cytokines in active psoriasis: A relation to coexistent arthropathy
7. Expression of the psoriasis-associated antigen, Pso p27, is inhibited by cyclosporin A
8. Eosinophils, pruritus and psoriasis: Effects of treatment with etretinate or cyclosporin A
9. Cyclosporine and angiogenesis in psoriasis
10. Angiogenesis: Models and modulators
11. Altered expression of the a2 laminin chain in psoriatic skin: The effect of treatment with cyclosporin
12. Initiating neoral therapy
13. Terapia sistemica nella psoriasi
14. Current management of psoriasis. Cyclosporin
15. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis
16. Neoral® in the treatment of psoriasis: Consensus treatment guidelines
17. Potential drug interaction with CsA
18. Efficacy of low-dose cyclosporin a in psoriasis: Results of dose-finding studies
19. Individualized short-course cyclosporin therapy in psoriasis
20. Neoral in psoriasis therapy: Toward a new perspective
21. A multicentre evaluation of the guidelines for the use of cyclosporin A in severe psoriasis
22. Short and long-term considerations conserning the management of claque psoriasis with low-dose cyclosporine
23. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study
24. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: A 1-year multicentre, randomized study
25. Dynamics of psoriatic trachyonychia during low-dose cyclosporin A treatment: A pilot study on onychochronobiology using optical profilometry
26. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin
27. Efficacy of cyclosporin A in psoriasis: A summary of the United States' experience
28. Pustular psoriasis
29. Treatments of generalized pustular psoriasis: A multicenter study in Japan
30. Low-dose cyclosporin A in severe psoriatic arthritis: Clinical results of a long-term study
31. Therapy with cyclosporine in psoriatic arthritis
32. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis
33. Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre study
34. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
35. Conversione della ciclosporina in formulazione tradizionale a quella in microemulsione (Neoral®)
36. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study
37. Combination of cyclosporin A and topical corticosteroid in the treatment of psoriasis
38. Short contact anthralin treatment augments theurapetic efficacy of cyclosporine in psoriasis: A clinical and pathologic study
39. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris
40. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis
41. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis
42. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports)
43. Cyclosporine and methotrexate: A dangerous combination
44. Combination low-dose cyclosporin (Neoral®) and hydroyurea for severe recalcitrant psoriasis
45. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: The Methotrexate-Cyclosporine Combination Study Group
46. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: An open-label extension study: The Methotrexate-Cyclosporine Combination Study Group
47. Combination treatment with methotreate and cyclosporin for severe recalcitrant psoriasis
48. Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis
49. Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study
50. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis
51. Renal biopsy findings in long-term cyclosporin treatment of psoriasis
52. Renal function after 10 years' treatment with cyclosporin for psoriasis
53. Efficacy of cyclosporin A (CyA) in psoriasis: An overview of dose/response, indications, contraindications and side-effects
54. Role of prostanoids and endothelins in prevention of cyclosporine-induced nephrotoxicity
55. Cyclosporin, nifedipine and gingival hyperplasia: A randomized controlled study
56. Side-effect profile of cyclosporin A in patients treated for psoriasis
57. Changes in peripheral blood lymphocyte subsets during cyclosporin administration in patients with psoriasis vulgaris
58. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and CsA treatment: Response to long-term acitretin maintenance